title: [Recent advances in the treatment of antineutrophil cytoplasm antibody associated vasculitides].
abstract: The authors review the nomenclature of vasculitides and the classification of antineutrophil cytoplasm antibody associated vasculitides and present the method of measuring disease activity (Five-factor Score, Birmingham Vasculitis Activity Score) and its role in defining therapeutical needs. They discuss the treatment algorithm of antineutrophil cytoplasm antibody associated vasculitides, present the sometimes equipotential medications used during the induction therapy followed by a maintenance regimen, and outline their usage and possible side-effects that may require medical attention. They point out the importance of plasmapheresis as an adjunctive treatment in some cases, as well as indications and possible outcome of kidney transplantation in therapy-resistant cases. Finally, they review several ongoing clinical studies, as their outcome will probably influence therapeutical opportunities of antineutrophil cytoplasm antibody associated vasculitides in the next few years.
authors.affiliation: Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó út 38-40., 1023.
authors.forename: Melinda Zsuzsanna
authors.initials: MZ
authors.lastname: Szabó
authors.affiliation: Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó út 38-40., 1023.
authors.forename: Patrícia
authors.initials: P
authors.lastname: Pálfi
authors.affiliation: Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó út 38-40., 1023.
authors.forename: Anna
authors.initials: A
authors.lastname: Bazsó
authors.affiliation: Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó út 38-40., 1023.
authors.forename: Gyula
authors.initials: G
authors.lastname: Poór
authors.affiliation: Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó út 38-40., 1023.
authors.forename: Emese
authors.initials: E
authors.lastname: Kiss
mesh_terms: D000465:Algorithms; D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D014890:Granulomatosis with Polyangiitis / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D008727:Methotrexate / Q000627:therapeutic use; D055953:Microscopic Polyangiitis / Q000628:therapy; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010956:Plasmapheresis; D011379:Prognosis; D000069283:Rituximab / Q000627:therapeutic use; D012720:Severity of Illness Index; D009626:Terminology as Topic
chemical_list: D007166:Immunosuppressive Agents; D000069283:Rituximab; D009173:Mycophenolic Acid; D001379:Azathioprine; D008727:Methotrexate
keywords: antineutrofil citoplazmatikus antitest asszociált vasculitis; antineutrophil cytoplasm antibody associated vasculitis; ciklofoszfamid; cyclophoshamide; plasmapheresis; plazmaferézis; rituximab; tituximab